Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus PEDIAMYCIN 400.
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin ethylsuccinate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation. Sulfisoxazole acetyl is a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Erythromycin ethylsuccinate (400 mg) and sulfisoxazole acetyl (600 mg) per 5 mL suspension: 2-3 teaspoonfuls (10-15 mL) orally every 6 hours for 10-14 days. Maximum daily dose: 6 g sulfisoxazole.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Erythromycin: terminal half-life of 1.4-2.0 hours in adults; prolonged to 4-6 hours in anuria. Sulfisoxazole: half-life 4.5-7 hours in adults; increased in renal impairment. The combination's clinical context warrants dosing interval adjustments in renal dysfunction.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Erythromycin ethylsuccinate is primarily excreted in bile (up to 80% as unchanged drug), with about 12-15% eliminated renally. Sulfisoxazole acetyl is renally excreted, with approximately 85% of the dose appearing in urine as acetylated and deacetylated metabolites. Fecal elimination accounts for less than 10% of sulfisoxazole.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic